Investor relations

Investor relations

CEO Comments August 3, 2022

Top-line results of Phase III AGENT Study – Did not meet primary or key secondary endpoints

“We are all surprised and disappointed in the results as we invested so much hope into improving the treatment for patients suffering mCRC. I would like to thank all the patients, clinical investigation sites and other participants that contributed to the study,” said Ulf Jungnelius, CEO of Isofol. “We will complete the data analysis before confirming next steps and look forward to working with regulatory agencies to consider alternative paths forward. Decisions related to Isofol’s clinical program will be on hold until we’ve consulted with relevant regulatory bodies which is tentatively planned during the first half of 2023.”

Ulf Jungnelius

Ulf Jungnelius - CEO

SEE HOW ARFOLITIXORIN
WORKS IN CANCER CELLS

About the AGENT study

Want to know more about the AGENT study and the drug candidate arfolitxorin?

Read more

Last updated 08-04-2022